Paper Details

  1. Home
  2. Paper Details

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial.

Author: FossJ F, MossJ, O'ConnorM, RoizenM F, ToledanoA, YuanC S

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Methylnaltrexone, a quaternary opioid antagonist, effectively prevented morphine-induced changes in gastrointestinal motility and transit without affecting analgesia in humans. This suggests potential for methylnaltrexone as an adjunct to opioids for managing opioid-induced constipation.
Paper Details　
Original Abstract of the Article :
Methylnaltrexone is a quaternary opioid antagonist with limited ability to cross the blood-brain barrier and the potential to antagonize the peripherally mediated effects of opioids. The effectiveness of methylnaltrexone in preventing morphine-induced changes in gastrointestinal motility and transit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0009-9236(96)90117-4

データ提供：米国国立医学図書館（NLM）

Methylnaltrexone: A Desert Oasis for Opioid-Induced Constipation?

Opioids, powerful pain relievers, can have a significant impact on the digestive system, causing constipation. This research delves into the potential of methylnaltrexone, a drug that blocks the effects of opioids in the gut, in mitigating this side effect. Think of opioids as a desert mirage that can be deceiving – while they offer relief, they can also leave you stranded in the desert of constipation.

Methylnaltrexone: A Potential Desert Oasis for Opioid Users?

The study found that methylnaltrexone effectively prevented morphine-induced delays in oral-cecal transit time without affecting the analgesic effect of morphine. It's like finding a hidden oasis that provides relief from constipation without diminishing the benefits of the mirage. The study suggests that methylnaltrexone could be a valuable tool for managing opioid-induced constipation, offering a safe and effective route out of the desert.

Navigating the Desert of Opioid Side Effects

The study highlights the potential of methylnaltrexone as a desert oasis for opioid users, offering a solution to the common side effect of constipation without compromising the benefits of pain relief. It's like finding a safe passage through the desert, allowing you to enjoy the mirage without becoming stranded in the discomfort of constipation. However, it's important to consult with a healthcare professional to determine if methylnaltrexone is right for you.

Dr.Camel's Conclusion

This research offers a potential oasis in the desert of opioid-induced constipation, suggesting that methylnaltrexone could provide relief without affecting the analgesic effects of morphine. It's like finding a safe and effective way to navigate the desert of opioid side effects, allowing you to enjoy the benefits of pain relief without becoming trapped in the discomfort of constipation.

Date :
  1. Date Completed 1996-06-05
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

8612393

DOI: Digital Object Identifier

10.1016/S0009-9236(96)90117-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.